Recent news on Miglustat

Actelion announces first quarter results 2007  -  Apr 19, 2007
PharmaLive.com (press release),Zavesca® (miglustat) is commercially available in the United States and in most European markets. On 5 March 2007, the double-blind, placebo-controlled,

Stem cells have multiple brain benefits  -  Mar 12, 2007
DrugResearcher.com,Zavesca (miglustat) is now marketed by Actelion and is approved to treat Gaucher's disease - another disease caused by the build up of lipids.

Net income almost doubles at Switzerland's Actelion  -  Feb 22, 2007
Pharma Times (subscription),Also contributing to Actelion's coffers was Zavesca (miglustat), its new treatment for Gaucher disease, which brought in 25.4 million francs,

Actelion Announces Full Year 2006 Financial Results  -  Feb 21, 2007
Primenewswire (press release),In 2007, Actelion also expects to initiate a proof-of-concept study with miglustat (Zavesca(r)) in an undisclosed indication. In addition, the company

The Consumer Contraception as an Option for the Man  Nov 6, 2006
Two weeks ago, researchers at the University of Washington reported that yet another promising candidate, miglustat, which produced infertility in certain mice ... -New York Times, Male Contraception: Are We Getting Close?  -  Nov 17, 2006
Keep the Doctor Away,The latest promising contraceptive that didn't make the leap from mice to men is miglustat (trade name Zavesca). The drug is already approved and on the

Actelion Announces Half Year Financial Results 2006  Jul 19, 2006
Enrollment for this Phase III trial will start before year-end. -- The MAINTENANCE program, evaluating the long-term safety and efficacy of miglustat (Zavesca(r ... -PrimeZone

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional